Table 2 Meta-analysis of combined neuropsychiatric CNV association with ADHD in Icelandic and Norwegian samples

From: Attention-deficit hyperactivity disorder shares copy number variant risk with schizophrenia and autism spectrum disorder

Neuropsychiatric CNVs

Iceland carrier frequency (%)d

OR (95% CI), P correctede

Norway carrier frequency (%)d

OR (95% CI), P correctede

Combined carrier frequency (%)f

OR (95% CI), Pf

Combineda

1.89/0.834

2.30 (1.86, 2.80), 1.4 × 10−11

2.54/0.971

2.66 (2.04, 3.43), 7.7 × 10−12

2.15/0.855

2.43 (2.05, 2.87), 1.6 × 10−21

Combinedb

0.389/0.235

1.66 (1.03, 2.55), 0.041

0.557/0.230

2.43 (1.35, 4.18), 0.0034

0.456/0.235

1.94 (1.33, 2.76), 6.0 × 10−4

Combinedc

0/0.0264

0 (0, 2.58), 0.44

0.0928/0.0234

3.97 (0.64, 18.59), 0.075

0.0380/0.0257

1.38 (0.27, 4.42), 0.49

  1. aAll 19 combined: 1q21.1 distal—deletion, 1q21.1 distal—duplication, 2p16.3 (NRXN1)—deletion, 3q29—deletion, 7q11.23 (WBS)—duplication, 7q36.3 (VIPR2)—duplication, 15q11.2—deletion, 15q11.2–13.1—duplication, 15q13.3 (BP4 & BP4.5–BP5)—deletion, 16p11.2 distal—deletion, 16p11.2 proximal—deletion, 16p11.2 proximal—duplication, 16p12.1—deletion, 16p13.11—duplication, 17p12—deletion, 17q12—deletion, 17q12—duplication, 22q11.21—deletion, 22q11.21—duplication
  2. bRemoved eight individually significant CNVs (Fig. 1, Table 1 and Supplementary Table 3) and tested: 1q21.1 distal—deletion, 3q29—deletion, 7q11.23 (WBS)—duplication, 7q36.3 (VIPR2)—duplication, 15q11.2–13.1—duplication, 16p11.2 distal—deletion, 16p11.2 proximal—deletion, 16p12.1—deletion, 17p12—deletion, 17q12—deletion, 17q12—duplication
  3. cCombined individually untested CNVs from Supplementary Table 4: 3q29—deletion, 7q11.23 (WBS)—duplication, 7q36.3 (VIPR2)—duplication, 15q11.2–13.1—duplication, 17q12—deletion
  4. dThe affected/control carrier frequencies were calculated from the combined number of CNV carriers divided by the combined number of genotyped individuals in the Icelandic and Norwegian sample separately, before adjusting the counts for relatedness. Iceland ADHD affected (N = 5650) and controls (N = 155,122), and Norwegian ADHD affected (N = 3233) and controls (N = 25,654)
  5. eOdds ratio (OR), 95% confidence interval (95% CI) and P value are estimated using Fisher's exact to test for increased burden of the neuropsychiatric CNVs in the ADHD cases compared with controls in the Icelandic or Norwegian samples. The P values were adjusted with a correction factor (1.187 in Iceland and 1.033 in Norway) using the intercept from LD score regression41
  6. fThe Icelandic and Norwegian carrier frequency (in percent) was calculated from affected/control, carrier and non-carrier counts, adjusted for relatedness with a correction factor (1.187 in Iceland and 1.033 in Norway) using the intercept from LD score regression41, and rounded to the nearest integer, and then to estimate OR combined using the Cochran–Mantel–Haenszel χ2 test for count data. Iceland and Norwegian combined ADHD affected (N = 7890) and controls (N = 155,519)
Back to article page